<SUBMISSION>
<ACCESSION-NUMBER>0001157523-07-009619
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20070927
<ITEMS>5.02
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20071003
<DATE-OF-FILING-DATE-CHANGE>20071003
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NeoStem, Inc.
<CIK>0000320017
<ASSIGNED-SIC>8090
<IRS-NUMBER>222343568
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-33650
<FILM-NUMBER>071154311
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>420 LEXINGTON AVENUE
<STREET2>SUITE 450
<CITY>NEW YORK
<STATE>NY
<ZIP>10170
<PHONE>212-584-4171
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>420 LEXINGTON AVENUE
<STREET2>SUITE 450
<CITY>NEW YORK
<STATE>NY
<ZIP>10170
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>PHASE III MEDICAL INC/DE
<DATE-CHANGED>20030819
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>CORNICHE GROUP INC /DE
<DATE-CHANGED>19951117
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>FIDELITY MEDICAL INC
<DATE-CHANGED>19951025
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a5509275.txt
<DESCRIPTION>NEOSTEM, INC. 8-K
<TEXT>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): September 27, 2007

                                  NEOSTEM, INC.
             (Exact name of registrant as specified in its charter)


           Delaware                   0-10909                    22-2343568
           --------                   -------                    ----------
(State or Other Jurisdiction        (Commission                (IRS Employer
       of Incorporation)            File Number)             Identification No.)


  420 Lexington Avenue, Suite 450
         New York, New York                                         10170
--------------------------------------------------------------------------------
(Address of principal executive offices)                          (Zip Code)

       Registrant's telephone number, including area code: (212) 584-4180

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

                                      -1-
<PAGE>

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

     (e) Effective as of September 27, 2007, NeoStem, Inc. (the "Company")
entered into a letter agreement with Dr. Robin L. Smith, its Chairman of the
Board and Chief Executive Officer, pursuant to which Dr. Smith's employment
agreement dated as of May 26, 2006 and amended as of January 26, 2007, was
further amended to provide that: (a) Dr. Smith's base salary would be increased
to $275,000 (the amount to which Dr. Smith would have been entitled under her
original employment agreement prior to her agreement on January 26, 2007 to
accept a reduced salary of $250,000); (b) her base salary would be increased by
10% on each one year anniversary of the agreement; (c) a cash bonus of $187,500
(an amount equal to 75% of her base salary) would be paid October 1, 2007; (d)
Dr. Smith's bonus for 2008 is set in the amount of $250,000 (an amount equal to
100% of her base salary) to be paid October 1, 2008; and (e) the Company will
pay membership and annual fees for a club in New York of Dr. Smith's choice for
business entertaining and meetings. Other than as set forth therein, Dr. Smith's
original employment agreement and all amendments thereto remain in full force
and effect. On September 27, 2007 (the "Grant Date"), Dr. Smith was also granted
(i) 30,000 shares of restricted common stock pursuant to and subject to the
Company's 2003 Equity Participation Plan ("2003 EPP") in her capacity as a
member of the Company's Board of Directors, 15,000 of which vested on the Grant
Date and 15,000 of which is scheduled to vest on the first anniversary of the
Grant Date, subject to Dr. Smith's continued employment; and (ii) an option
pursuant to and subject to the 2003 EPP to purchase 250,000 shares of the Common
Stock at a per share exercise price equal to $4.95 (the per share closing price
of the Company's common stock on the American Stock Exchange on the Grant Date)
vesting as to (i) 150,000 shares immediately and (ii) 100,000 shares upon the
achievement of certain specified business milestones.

     Effective as of September 28, 2007, the Company entered into a letter
agreement with Mark Weinreb, its President, pursuant to which Mr. Weinreb's
employment agreement dated as of February 6, 2005 and amended as of August 12,
2005 and June 1, 2006 (together, the "Agreement") (such Agreement being
supplemented as of January 26, 2007, the effectiveness of which supplement has
expired by its terms), was further amended to provide that: (a) Mr. Weinreb's
base salary would be increased from $200,000 to $210,000; (b) the sole bonus to
which he will be entitled shall be a quarterly bonus of $7,500 payable at the
end of each quarterly period during the term commencing as of September 30,
2007; (c) in the event of termination of employment, any severance to which Mr.
Weinreb is entitled under the Agreement shall equal the lesser of one year of
his base salary or his base salary payable for the remainder of the term, in
each case paid out over a 12 month period in accordance with the payroll
policies and practices of the Company; and (d) any unused vacation to which Mr.
Weinreb is entitled under the Agreement in any calendar year shall be forfeited
without compensation. Other than as set forth therein, Mr. Weinreb's Agreement
remains in full force and effect. On September 27, 2007, Mr. Weinreb was also
granted (i) 30,000 shares of restricted common stock pursuant to and subject to
the Company's 2003 EPP in his capacity as a member of the Company's Board of
Directors, 15,000 of which vested upon the Grant Date and 15,000 of which is
scheduled to vest on the first anniversary of the Grant Date, subject to Mr.
Weinreb's continued employment; (ii) an additional 10,000 shares of restricted
common stock pursuant to and subject to the 2003 EPP, 5,000 of which vested upon
the Grant Date and 5,000 of which is scheduled to vest on the first anniversary
of the Grant Date, subject to Mr. Weinreb's continued employment; and (iii) an
option pursuant to and subject to the 2003 EPP to purchase 50,000 shares of the
Common Stock at a per share exercise price equal to $4.95 (the per share closing
price of the Company's common stock on the American Stock Exchange on the Grant
Date) vesting as to 10,000 shares immediately and 40,000 shares upon the
achievement of certain specified business milestones.

                                      -2-
<PAGE>

     On September 27, 2007, Larry A. May, the Company's Chief Financial Officer,
was granted (i) 10,000 shares of restricted common stock pursuant to and subject
to the 2003 EPP, 5,000 of which vested upon the Grant Date and 5,000 of which is
scheduled to vest on the first anniversary of the Grant Date, subject to Mr.
May's continued employment; and (ii) an option pursuant to and subject to the
2003 EPP to purchase 20,000 shares of the Common Stock at a per share exercise
price equal to $4.95 (the per share closing price of the Company's common stock
on the American Stock Exchange on the Grant Date) vesting as to 5,000 shares
immediately and 15,000 shares upon the achievement of certain specified business
and other milestones. Mr. May also was awarded a cash bonus of $13,200 (an
amount equal to 10% of a prior annual base salary).

     On September 27, 2007, Catherine M. Vaczy, the Company's Vice President and
General Counsel, was granted (i) 30,000 shares of restricted common stock
pursuant to and subject to the Company's 2003 EPP in her capacity as Secretary
of the Company's Board of Directors, 15,000 of which vested upon the Grant Date
and 15,000 of which is scheduled to vest on the first anniversary of the Grant
Date, subject to Ms. Vaczy's continued employment; (ii) an additional 15,000
shares of restricted common stock pursuant to and subject to the 2003 EPP, 7,500
of which vested upon the Grant Date and 7,500 of which is scheduled to vest on
the first anniversary of the Grant Date, subject to Ms. Vaczy's continued
employment; and (iii) an option pursuant to and subject to the 2003 EPP to
purchase 35,000 shares of the Common Stock at a per share exercise price equal
to $4.95 (the per share closing price of the Company's common stock on the
American Stock Exchange on the Grant Date) vesting as to 15,000 shares
immediately and 20,000 shares upon the achievement of certain specified business
milestones. Ms. Vaczy also was awarded a cash bonus of $37,500 (an amount equal
to 25% of her annual base salary).

     The foregoing arrangements were approved by the Compensation Committee of
the Board of Directors of the Company.

Item 8.01. Other Events.

     On September 27, 2007, pursuant to and subject to the 2003 EPP, the
Compensation Committee of the Board of Directors of the Company authorized the
issuance of an aggregate of 332,000 shares of its restricted common stock, par
value $0.001 per share, and options to purchase an aggregate of 457,000 shares
of common stock at a per share exercise price equal to $4.95 (the per share
closing price of the Company's common stock on the American Stock Exchange on
the Grant Date), to certain of its officers, directors, employees and
consultants, inclusive of the amounts set forth in Item 5.02 above.

Item 9.01. Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit 10.1 September 27, 2007 Amendment to Employment Agreement of
             Robin L. Smith

Exhibit 10.2 September 28, 2007 Amendment to Employment Agreement of
             Mark Weinreb

                                      -3-

<PAGE>

                                    SIGNATURE
                                    ---------

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                          NEOSTEM, INC.


                                          By: /s/ Catherine M. Vaczy
                                              Catherine M. Vaczy
                                              Vice President and General Counsel


Dated: October 3, 2007

                                      -4-
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a5509275ex101.txt
<DESCRIPTION>EXHIBIT 10.1
<TEXT>

                                                                    Exhibit 10.1


September 27, 2007


Dr. Robin L. Smith
930 Fifth Avenue
Suite 8H
New York, NY  10021

Dear Robin:

This letter is being written to serve as an amendment to the employment
agreement by and between you and NeoStem, Inc. (the "Company") dated as of May
26, 2006 pursuant to which you serve as the Company's Chairman of the Board and
Chief Executive Officer (the "Agreement") and letter dated January 26, 2007.
Except as set forth herein, your employment agreement shall remain unchanged.
Initially capitalized terms used herein but not defined herein shall have the
meaning set forth in the Agreement.

1.   Base Salary.
On October 1, 2007, your Base Salary shall be increased to $275,000. During the
Term of the Agreement, your Base Salary shall be increased by 10% on each one
year anniversary of the execution of this Amendment.

2.   Cash and Stock Bonuses.
$187,500 cash bonus shall be paid for 2007 on October 1, 2007. $250,000 cash
bonus shall be paid for 2008 on October 1, 2008. Additionally, the company will
pay membership and annual fees for a club in NY of your choice that can be used
for business entertainment, meetings etc.

3.   Term.
The Term of the Agreement is hereby extended until December 31, 2010.

4.   Severance
Section 7(b)(i) of the Agreement is hereby amended to read in its entirety as
follows:

        "(b) Termination of Your Employment by the Company Without Cause or
        Voluntary Termination by You With Good Reason. If the Company terminates
        your employment without Cause or if you terminate your employment with
        Good Reason the following shall apply:

           (i) The Company shall pay to you the Base Salary at the time of
           termination for a period equal to two years following the date of
           such termination (the "Severance Period"). Payments of severance can
           be

                                      -5-
<PAGE>

           paid in equal installments over a 12 month period to begin the day of
           termination. You shall be under no obligation to secure alternative
           employment during the Severance Period, and payment of the Base
           Salary shall be made without regard to any subsequent employment you
           may obtain."

5.   Acknowledgement of Stock Option Grant.
You hereby acknowledge the grant to you on Sept 27, 2007 of an option under the
EPP to purchase 250,000 shares of the Company's common stock, $.001 par value
(the "Common Stock") at a per share exercise price equal to market vesting as to
(i) 150,000 shares now; (ii) 100,000 shares upon the achievement of certain
business milestones set by the compensation committee, and shall otherwise be
subject to all of the terms and conditions of the EPP.

Except as provided in this letter agreement, the terms of the Employment
Agreement shall remain unchanged.

Very truly yours,

NeoStem, Inc.
By:  /s/ Richard Berman
Name:  Richard Berman
Title:  Chair, Compensation Committee

Accepted and Agreed:

/s/ Robin Smith
Robin Smith

                                      -6-
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a5509275ex102.txt
<DESCRIPTION>EXHIBIT 10.2
<TEXT>

                                                                    Exhibit 10.2


September 28, 2007

Mr. Mark Weinreb
9 Colgate Lane
Woodbury, NY  11797

Dear Mark:

This letter is being written to serve as an amendment to the employment
agreement dated February 6, 2003 by and between you and NeoStem, Inc. (formerly
Corniche Group Incorporated and Phase III Medical, Inc.) (the"Company"), as
amended, pursuant to which you serve as the Company's President (the
"Agreement").

On October 1, 2007, your Base Salary shall be increased to $210,000. The sole
bonus to which you are entitled under the Agreement shall be a quarterly bonus
of $7500 payable at the end of each quarterly period during the term commencing
as of September 30, 2007. Any unused vacation to which you are entitled under
the Agreement in any calendar year shall be forfeited without compensation.
Further, in the event of any termination of the Agreement, any severance
payments to which you are entitled under the Agreement shall equal the lesser of
one year of your base salary or your base salary payable for the remainder of
the term of the Agreement, in each case paid out in equal installments over a
twelve (12) month period in accordance with the Company's payroll practices.

Except as provided in this letter agreement, the terms of the Agreement shall
remain unchanged.

Very truly yours,

NeoStem, Inc.

By: /s/ Robin Smith
Name:  Robin Smith, Chairman and CEO

Accepted and Agreed:

/s/ Mark Weinreb
Mark Weinreb

                                      -7-
</TEXT>
</DOCUMENT>
</SUBMISSION>
